NVS - Novartis Sandoz Prepares For Public Debut With Strong Sales Record And Plans for New Biologic Drugs | Benzinga
Novartis AG (NYSE: NVS) confirmed its plans for a 100% spin-off of the Sandoz business on October 4 after shareholders approved it earlier this month.
Novartis also said key regulatory approvals have been obtained, including the approval by SIX Exchange Regulation for listing the Sandoz shares on the SIX Swiss Exchange. The Sandoz shares will have the symbol SDZ, Novartis said.
Deutsche ...